NewAmsterdam out-licenses obicetrapib to Menarini in Europe

NewAmsterdam Pharma, a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, and privately-held Italian Menarini Group have announced an exclusive license agreement for the commercialization of obicetrapib, which, if approved in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases.

Obicetrapib is NewAmsterdam’s next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase IIb trials. Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s.

NewAmsterdam picked up obicetrapib when it acquired Dezima Pharma from Amgen in April 2020.